Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease

Nephron - Clinical Practice

Volumn 123, Issue 3-4, 2013, Pages 157-164

  Kocyigit, Ismail ^a   Yilmaz, Mahmut Ilker ^b   Orscelik, Ozcan ^a   Sipahioglu, Murat Hayri ^a   Unal, Aydin ^a   Eroglu, Eray ^a   Kalay, Nihat ^a   Tokgoz, Bulent ^a   Axelsson, Jonas ^c   Oymak, Oktay ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autosomal dominant polycystic kidney disease; Endothelial dysfunction; Uric acid

Indexed keywords

C REACTIVE PROTEIN; N(G),N(G) DIMETHYLARGININE; URIC ACID;

ADULT; ARTICLE; AUTOANALYZER; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERURICEMIA; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; CONTROLLED STUDY; FLOW MEDIATED VASODILATION; PATIENT ASSESSMENT; PREVALENCE; VASODILATATION;

ADULT; ARGININE; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; GLOMERULAR FILTRATION RATE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; URIC ACID; VASODILATION;

EID: 84880407638     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000353730     Document Type: Article

References (48)

1. Grantham JJ: Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359: 1477-1485.
2. Fick GM, Johnson AM, Hammond WS, Gabow PA: Causes of death in autosomal dominant polycystic kidney disease. J Am S Nephrol 1995; 5: 2048-2056.
3. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA: The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42: 1149-1160.
4. Wang D, Iversen J, Wilcox CS, Strandgaard S: Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal dominant polycystic kidney disease. Kidney nt 2003; 64: 1381-1388.
5. Khosla UM, Zharikov S, Finch JL, et al: Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739-1742.
6. Zoccali C, Maio R, Mallamaci F, Sesti G, Perticone F: Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006; 17: 1466-1471.
7. Kurowska EM: Nitric oxide therapies in vascular diseases. Curr Pharm Des 2002; 8: 155-166.
8. Portaluppi F, Boari B, Manfredini R: Oxidative stress in essential hypertension. Curr Pharm Des 2004; 10: 1695-1698.
9. Liu WC, Hung CC, Chen SC, et al: Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2012; 7: 541-48.
10. Wen CP, David Cheng TY, Chan HT, et al: Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk. Am J Kidney Dis 2010; 56: 273-288.
11. Mejías E, Navas J, Lluberes R, Martínez-Maldonado M: Hyperuricemia, gout, and autosomal dominant polycystic kidney disease. Am J Med Sci 1989; 297: 145-148.
12. Errasti P, Manrique J, Lavilla J, et al: Autosomal-dominant polycystic kidney disease: high prevalence of graft loss for death-related malignancies and cardiovascular risk factors. Transplant Proc 2003; 35: 1717-1719.
13. Kaehny WD, Tangel DJ, Johnson AM, Kimberling WJ, Schrier RW, Gabow PA: Uric acid handling in autosomal dominant polycystic kidney disease with normal filtration rates. Am J Med 1990; 89: 49-52.
14. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM: Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994; 343: 824-827.
15. Myers GL, Miller WG, Coresh J, et al; National Kidney Disease Education Program Laboratory Working Group: Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 2006; 52: 5-18.
16. Krishnan E, Kwoh CK, Schumacher HR, Kuller L: Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49: 98-303.
17. Grantham JJ, Chonko AM: Renal handling of organic anions and cations; excretion of uric acid; in Brenner BM, Rector FC (eds): The Kidney. Philadelphia, aunders, 991, pp 483-509.
18. Chen BM, Xia LW, Zhao RQ: Determination of N(G),N(G)-dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 692: 467.
19. Celermajer DS, Sorensen K, Ryalls M, et al: Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in heir heterozygous parents. J Am Coll Cardiol 1993; 22: 854-858.
20. Nadar S, Blann AD, Lip GY: Endothelial dysfunction: methods of assessment and application to hypertension. Curr Pharm Des 2004; 10: 3591-3605.
21. Charakida M, Masi S, Lüscher TF, Kastelein JJ, Deanfield JE: Assessment of atherosclerosis: the role of flow-mediated dilatation. Eur Heart J 2010; 31: 2854-2861.
22. Kanbay M, Yilmaz MI, Sonmez A, et al: Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am J Nephrol 2011; 3: 298-304.
23. Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821.
24. Kato M, Hisatome I, Tomikura Y, et al: Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol 2005; 96: 1576-1578.
25. Erdogan D, Gullu H, Caliskan M, et al: Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int J Clin Pract 005; 59: 1276-1282.
26. Victor VM, Rocha M, Solá E, Bañuls C, Garcia- Malpartida K, Hernández-Mijares A: Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des 2009; 15: 2988-3002.
27. Doehner W, Landmesser U: Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options. Semin Nephrol 2011; 31: 433-440.
28. Mercuro G, Vitale C, Cerquetani E, et al: Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol 2004;94: 932-935.
29. Kang DH, Park SK, Lee IK, Johnson RJ: Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553-3562.
30. Zharikov S, Krotova K, Hu H, et al: Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol 2008; 295: 1183-1190.
31. Sánchez-Lozada LG, Soto V, Tapia E, et al: Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol 2008; 295:F1134-F1141.
32. Sánchez-Lozada LG, Tapia E, López-Molina R, et al: Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J Physiol Renal Physiol 2007; 292:F1238-F1244.
33. Duffy WB, Senekjian HO, Knight TF, Weinman EJ: Management of asymptomatic hyperuricemia. JAMA 1981; 246: 2215-2216.
34. Kanbay M, Huddam B, Azak A, et al: A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 2011; 6: 1887-1894.
35. Grayson PC, Kim SY, LaValley M, Choi HK: Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res 2011; 63: 102-10.
36. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA: Hyperuricemia and risk of stroke: a systematic review and metaanalysis. Arthritis Rheum 2009; 61: 885-892.
37. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA: Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res 2010; 62: 170-180.
38. Yu MA, Sanchez-Lozada LG, Johnson RJ, Kang DH: Uric acid: an inducer of oxidative stress and renin-angiotensin system in human vascular endothelial cells. J Hyper tens 2010; 28: 1234-1242.
39. Yilmaz MI, Sonmez A, Saglam M, et al: ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol 2008; 19: 388-395.
40. Ecder T, Schrier RW: Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol 2009; 5: 221-228.
41. Wang D, Iversen J, Strandgaard S: Endothelium-dependent relaxation of small resistancevessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000; 11: 1371-1376.
42. Al-Nimri MA, Komers R, Oyama TT, Subramanya AR, Lindsley JN, Anderson S: Endothelial-derived vasoactive mediators in polycystic kidney disease. Kidney Int 2003; 63: 1776-1784.
43. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-954.
44. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-2678.
45. Zoccali C, Bode-Böger S, Mallamaci F, et al: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117.
46. Wang D, Strandgaard S, Borresen ML, et al: Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am J Kidney Dis 2008; 51: 184-191.
47. Kocaman O, Oflaz H, Yekeler E, et al: Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2004; 43: 854-860.
48. Ruggenenti P, Gaspari F, Cannata A, et al; GFR-ADPKD Study Group: Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study. PLoS One 2012; 7:e32533.